Trevena Company Profile (NASDAQ:TRVN)

Trevena trades on the NASDAQ under the ticker symbol "TRVN."

Trevena, Inc. (NASDAQ:TRVN) posted its earnings results on Thursday, August, 3rd. The company reported ($0.35) earnings per share (EPS) for the quarter, meeting the Zacks' consensus estimate of ($0.35). View Trevena's Earnings History.

Trevena is scheduled to release their next quarterly earnings announcement on Wednesday, November, 1st 2017. View Earnings Estimates for Trevena.

11 brokers have issued 1-year price targets for Trevena's shares. Their predictions range from $8.00 to $16.00. On average, they anticipate Trevena's share price to reach $11.27 in the next twelve months. View Analyst Ratings for Trevena.

Here are some recent quotes from research analysts about Trevena stock:

• 1. According to Zacks Investment Research, "Trevena, Inc. is a biopharmaceutical company. It focuses on discovering and developing therapeutics for G protein coupled receptors. The Company's product pipeline includes TRV027, TRV130, TRV734 and Delta opioid biased ligand which are in different clinical phases. Trevena, Inc. is based in King of Prussia, Pennsylvania. " (8/25/2017)
• 2. Needham & Company LLC analysts commented, "Trevena announced 1Q17 financial results yesterday. Olinvo NDA submission in pain still on track for 4Q17. Phase 3 open-label ATHENA safety trial has reached 600pt enrollment. Company therefore likely to reach target 1100 pt exposures per FDA recommendation (~480pts treated in APOLLO trials) in near future. As a reminder, Olinvo Phase 3 APOLLO trials did not establish consistent statistically significant differentiation from morphine on secondary GI and respiratory endpoints. We believe observed trend was clinically meaningful, but have updated our models to reflect modest market penetration given likely challenges in communicating differentiation." (5/5/2017)
• 3. Cowen and Company analysts commented, "TRVN reported 4Q16 results." (3/22/2017)
• 4. HC Wainwright analysts commented, "Following the Phase 3 pivotal APOLLO readouts, and the subsequent ~45% drop in TRVN shares (vs. -1.5% NBI) over the last two trading sessions, we assess the implications of the mixed data set, and suggest likely/ probable clinical settings for use that best match OLINVO's (new brand name for oliceridine) overall therapeutic profile' we believe some physicians may find OLINVO useful at reducing antiemetic use, especially in hard tissue pain (most commonly, knee and hip surgery). Yet despite a more nuanced view than some, we nonetheless acknowledge that APOLLO results are far from the "clean win" we were hoping for." (2/23/2017)
• 5. Aegis analysts commented, "After presenting results yesterday, Trevena finished the trading day down approximately 40%. We believe there are several contributing factors: (1) the lowest dose 0.1 mg did not prove non-inferiority to that of morphine; (2) on the safety side, improvements on the respiratory and nausea/vomiting measurement did not show statistical significance to that of Morphine; (3) investors may think that the current data set points to an Oliceridine that has no commercial value proposition relative to that of morphine. This could lead to slow market adoption; (4) the company may need a capital raise before the NDA is accepted. If a capital raise is completed with current share price, this may lead to excessive dilution; (5) the Athena open label study may be a little behind schedule which puts further pressure on cash runway of the company. We will be buyers on weakness. We view the situation quite differently. The most important thing in our eye's is that Trevena is likely to have enough data for an NDA in 4Q17 after the Athena trial is completed." (2/22/2017)

Some companies that are related to Trevena include Minerva Neurosciences (NERV), Athersys (ATHX), Oxford BioMedica plc (OXB), Immune Design Corp. (IMDZ), Arrowhead Pharmaceuticals (ARWR), Forward Pharma A/S (FWP), Stemline Therapeutics (STML), Ardelyx (ARDX), DURECT Corporation (DRRX), uniQure N.V. (QURE), Kura Oncology (KURA), Circassia Pharmaceuticals PLC (CIR), Chimerix (CMRX), Pieris Pharmaceuticals (PIRS), Tocagen (TOCA), Mast Therapeutics (SVRA), Faron Pharmaceuticals Oy (FARN) and ObsEva SA (OBSV).

Trevena's management team includes the folowing people:

• Leon O. Moulder Jr., Independent Chairman of the Board
• Maxine Gowen Ph.D., President, Chief Executive Officer, Director
• Roberto E. Cuca, Chief Financial Officer, Senior Vice President
• Michael W. Lark Ph.D., Senior Vice President - Research, Chief Scientific Officer
• John M. Limongelli Esq., Senior Vice President, General Counsel, Corporate Secretary
• Carrie L. Bourdow, Senior Vice President, Chief Commercial Officer
• Yacoub Habib Ph.D., Senior Vice President - Business Development and Corporate Planning
• David Soergel M.D., Senior Vice President - Clinical Development , Chief Medical Officer
• Michael R. Dougherty, Independent Director
• Adam M. Koppel M.D. Ph.D., Independent Director

Trevena's stock is owned by a number of of institutional and retail investors. Top institutional investors include FMR LLC (8.56%), NEA Management Company LLC (6.54%), Vanguard Group Inc. (3.13%), Vivo Capital LLC (2.96%), Northpointe Capital LLC (2.10%) and Balyasny Asset Management LLC (1.36%). Company insiders that own Trevena stock include Carrie L Bourdow, David Soergel, Maxine Gowen and Yacoub Habib. View Institutional Ownership Trends for Trevena.

Trevena's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Balyasny Asset Management LLC, Wells Fargo & Company MN, GSA Capital Partners LLP and Bank of New York Mellon Corp. View Insider Buying and Selling for Trevena.

Trevena's stock was bought by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Vanguard Group Inc., Northern Trust Corp, State Street Corp, Northpointe Capital LLC, Virtu KCG Holdings LLC, Nationwide Fund Advisors and Teachers Advisors LLC. Company insiders that have bought Trevena stock in the last two years include Carrie L Bourdow, Maxine Gowen and Yacoub Habib. View Insider Buying and Selling for Trevena.

Shares of Trevena can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Trevena stock can currently be purchased for approximately $2.46.